Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Tomas Jelinek; Tereza Sevcikova; David Zihala; Tereza Popkova; Veronika Kapustova; Lucie Broskevicova; Lenka Capkova; Lucie Rihova; Renata Bezdekova; Sabina Sevcikova; Vladimir Zidlik; Martin Havel; Hana Plonkova; Alexandra Jungova; Jiri Minarik; Martin Stork; Ludek Pour; Petr Pavlicek; Ivan Spicka; Vladimir Maisnar; Jakub Radocha; Michal Simicek; Roman Hajek

doi:10.1038/s41375-021-01343-w

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Leukemia. 2022 Jan;36(1):288-291. doi: 10.1038/s41375-021-01343-w. Epub 2021 Jul 10.

Authors

Tomas Jelinek¹, Tereza Sevcikova², David Zihala², Tereza Popkova², Veronika Kapustova^{2

3}, Lucie Broskevicova², Lenka Capkova⁴, Lucie Rihova⁵, Renata Bezdekova⁵, Sabina Sevcikova⁶, Vladimir Zidlik⁷, Martin Havel⁸, Hana Plonkova², Alexandra Jungova⁹, Jiri Minarik¹⁰, Martin Stork¹¹, Ludek Pour¹¹, Petr Pavlicek¹², Ivan Spicka¹³, Vladimir Maisnar¹⁴, Jakub Radocha¹⁴, Michal Simicek², Roman Hajek²

Affiliations

¹ Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. tomas.jelinek.md@gmail.com.
² Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
³ Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
⁴ Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic.
⁵ Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
⁶ Babak Myeloma Group, Department of Pathofysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
⁷ Department of Pathology, University Hospital Ostrava, Ostrava, Czech Republic.
⁸ Department of Nuclear Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
⁹ Hematology and Oncology Department, Charles University Hospital Pilsen, Czechia, Czech Republic.
¹⁰ Department of Hematooncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czechia, Czech Republic.
¹¹ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czechia, Czech Republic.
¹² Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
¹³ 1st Medical Department-Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
¹⁴ 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.

PMID: 34247197
DOI: 10.1038/s41375-021-01343-w

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Clone Cells / drug effects*
Clone Cells / pathology
Follow-Up Studies
Humans
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Plasma Cells / drug effects*
Plasma Cells / pathology
Prognosis
Retrospective Studies
Survival Rate

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab